United Health Services will pay $5.25 per share for the online and mobile therapy company.
Four Israeli hospitals are ranked by “Newsweek” in the world’s top 250.
The company identifies, through an AI-based discovery platform, new radiotherapy drugs that could be effective.
The US biotech company will pay $149 million including milestone payments for the Rehovot-based cancer testing company.
Acting under the radar in the US, the Israeli company is revolutionizing orthopedic medicine and bone healing by introducing innovative fiber materials.
Novocure's share price jumped after it announced FDA approval for its device for treating pancreatic cancer with electric fields.
The medical devices giant will pay $585 million immediately for the company and with milestone payments the deal could reach $1 billion.
As the control battle for the aesthetic medicine company heats up, co-founder and CEO Moshe Mizrahy blasts activist investors and backs the employees.
After three consecutive years of growth, the Israeli pharmaceutical company predicts a small decline this year.
The Israeli company has developed an implant to protect healthy tissue from radiation damage.
American-Iranian investor Amir Heshmatpour made his fortune in US biotech companies. He’s now in Israel with NeOnc, developer of a nasally administered brain cancer drug.
An article published in “Nature” presents a new model that can predict the risk of diabetes 12 years in advance, based on data collected from continuous glucose monitoring.
Over a dozen pharma and biotech customers already use Converge's solutions for target discovery, antibody design, and protein manufacturing optimization.
Prof. Michael Hayden left Teva taking two products that it had begun developing. One became an almost $3.5 billion exit last September.
The main investors in Arkin Bio Ventures III together with Arkin Capital are Israeli institutional investors including Phoenix Finance, Clal Insurance, and Amitim pension fund.
Royalty Pharma will provide up to $500 million for development of a treatment for vitiligo.
Preliminary results released today show a 57% rise in fourth quarter revenue for the aesthetic medicine company.
Yitzhak Tshuva is expected to continue investing in the hospital network and establish at least one more hospital.
The survey of a representative sample of 1,100 people aged 20-75, was conducted immediately after the Gaza ceasefire in October-November 2025.
Four medical centers will officially operate in the Medica network, partly owned by the Leumit and Meuhedet health funds, from January.
The Israeli biopharmaceutical company will focus on developing drugs to treat schizophrenia and Alzheimer's psychosis.
Prof. Itzhak Fried tells "Globes" about the new research center he heads at Reichman University to explore the interface between the human brain and AI as well as his research on sleep and memory.
Under new CEO Eran Ophir, the Israeli drug discovery and development company has converted potential future royalties into immediate cash.
The company's share price rose 21% on Nasdaq last week.
The transfer from Yokne'am to Galway will be completed by 2028. Galil Medical employs about 100 people.
Leading medtech talent recruiter Joe Mullings explains why he's entering the Israeli market, and what Israeli founders looking for US personnel need to know.
Jerusalem-based Salignostics is also developing its saliva tests for diagnosing a range of infections.
Dalia Korkin risked everything to invest in nursing care company Amal Group and Beyond, and led it all the way to a NIS 2.6 billion IPO.
PathKeeper Surgical's spinal surgery device is radiation free and accurate to within less than a millimeter.
Prof. Yitshak Kreiss, CEO of Sheba Medical Center at Tel Hashomer, spoke to the Israel Conference about collaboration with Nvidia, and the remarkable survival rate in Israel hospitals.
"Keep InMode in Israel"